Literature DB >> 12325042

Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes.

Murat Oz1, Li Zhang, Marisela Morales.   

Abstract

The cloned 5-HT3 receptor from NCB-20 neuroblastoma cells was expressed in Xenopus oocytes and the effect of the endogenous cannabinoid ligand, anandamide, was investigated on the function of this receptor. The oocytes expressing the cloned 5-HT3 receptors were voltage-clamped at -70 mV. Anandamide, at the concentration range of 0.1-100 microM, reversibly inhibited 1 microM 5-HT induced currents. The inhibition of 5-HT induced currents by anandamide was concentration-dependent with an EC50 of 3.7 microM and slope value of 0.94. This inhibitory effect was not dependent on the membrane potential and anandamide did not have an effect on the reversal potential of 5-HT-induced currents. In the presence of 10 microM anandamide, the maximum 5-HT-induced response was also inhibited and the respective EC50 values were 3.4 microM and 3.1 microM in the absence and presence of anandamide, indicating that anandamide acts as a noncompetitive antagonist on 5-HT3 receptors. CB1 receptor antagonist SR-141716A (1 microM) and pertussis toxin (5 microg/ml) did not cause a significant change on the inhibition of 5-HT responses by anandamide. The effect of anandamide was not changed by preincubating the oocytes with 0.2 mM 8-Br-cAMP, a membrane-permeable analog of cAMP, or Sp-cAMPS (0.1 mM), a membrane-permeable protein kinase A activator. These results suggest that the effect of anandamide is independent of the activation of cAMP pathway and not mediated by the activation of PTX sensitive G-proteins. In conclusion, we demonstrated that the endogenous cannabinoid anandamide inhibits the function of 5-HT3 receptors expressed in Xenopus oocytes in a cannabinoid-receptor independent and noncompetitive manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12325042     DOI: 10.1002/syn.10121

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  12 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

3.  Inhibition of 5-HT(3) receptors-activated currents by cannabinoids in rat trigeminal ganglion neurons.

Authors:  Bo Shi; Rong Yang; Xiaohui Wang; Haixia Liu; Li Zou; Xiaoqun Hu; Jianping Wu; Anruo Zou; Linghua Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

4.  Identification of a high-affinity binding site involved in the transport of endocannabinoids.

Authors:  S A Moore; G G Nomikos; A K Dickason-Chesterfield; D A Schober; J M Schaus; B-P Ying; Y-C Xu; L Phebus; R M A Simmons; D Li; S Iyengar; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

5.  A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.

Authors:  Wei Xiong; Xiongwu Wu; Fuying Li; Kejun Cheng; Kenner C Rice; David M Lovinger; Li Zhang
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

6.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

Review 7.  Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.

Authors:  Gianluigi Tanda
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

8.  The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.

Authors:  V C J Wallace; A R Segerdahl; D M Lambert; S Vandevoorde; J Blackbeard; T Pheby; F Hasnie; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

Review 9.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

10.  Volatile anesthetics and endogenous cannabinoid anandamide have additive and independent inhibitory effects on alpha(7)-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes.

Authors:  Shelley N Jackson; Sachin K Singhal; Amina S Woods; Marisela Morales; Toni Shippenberg; Li Zhang; Murat Oz
Journal:  Eur J Pharmacol       Date:  2007-12-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.